Pharmacokinetic and pharmacodynamic analysis of cefoperazone/sulbactam for the treatment of pediatric sepsis by Monte Carlo simulation

Ye, Linhu; Cheng, Lei; Kong, Lingyun; ZHAO, Xinqian; Xie, Guoyan; He, Jing; Hong, Liu; Deng, Yan; Wu, Xinyu; Wang, Tingting; Wu, Hui; Yang, Xiaoxia

doi:10.1039/d1ay01385h

Anal. Methods

2022

DOI: 10.1039/d1ay01385h

|View full text |Cite

Pharmacokinetic and pharmacodynamic analysis of cefoperazone/sulbactam for the treatment of pediatric sepsis by Monte Carlo simulation

Linhu Ye

Lei Cheng²,

Lingyun Kong

et al.

Abstract: Pediatric sepsis syndrome is one of the most common reasons for pediatric intensive care unit hospitalization (PICU). Cefoperazone/sulbactam is a time‐dependent beta-lactamase inhibitor combination which has been widely used in...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

Salahshoori,

Golriz,

Nobre

et al. 2024

Journal of Molecular Liquids

View full text Add to dashboard Cite

Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

Salahshoori,

Golriz,

Nobre

et al. 2024

Journal of Molecular Liquids

View full text Add to dashboard Cite

Therapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study

Charoenwong,

Wacharachaisurapol,

Sukkummee

et al. 2024

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Rates of carbapenem-resistant Acinetobacter baumannii are rising in Thailand. Although high-dose (HD) sulbactam is recommended for treating carbapenem-resistant A. baumannii infections, data on plasma sulbactam concentrations in children are limited. We aimed to evaluate plasma sulbactam concentrations and pharmacokinetic-pharmacodynamic (PK-PD) target achievement in pediatric patients. Methods: Prospective study data (January–November 2023) on children (1 month–18 years) who received sulbactam every 6–8 hours were analyzed. Mid-dosing (C mid, 50% fT) and trough (C trough, 100% fT) concentrations were evaluated. PK-PD target achievement [50% fT > minimum inhibitory concentration (MIC), 100% fT > MIC] was evaluated using Clinical and Laboratory Standards Institute 2024 MIC cutoffs and MIC data of isolates of Acinetobacter calcoaceticus–baumannii complex from this study. Results: Thirty-five patients (median age 50 months) were categorized into standard-dose (SD) or HD groups. The geometric mean C mid was higher in the HD (41.3 mg/L) versus SD (19.5 mg/L) groups (P = 0.006). Among 101 isolates of Acinetobacter calcoaceticus–baumannii complex, the MIC50 and MIC90 (concentrations that inhibit 50% and 90% of isolates of the A. calcoaceticus–baumannii complex) were 16 and 128 mg/L, respectively. The HD group achieved C mid >MIC50 in 87.5% of the patients compared with 63.6% in SD (P = 0.17). Within the HD group, patients with augmented renal clearance (ARC) had lower C mid (geometric mean 31.9 mg/L) compared with non-ARC (geometric mean 63.4 mg/L) (P = 0.04). Conclusions: HD sulbactam resulted in higher C mid and PK-PD achievement. ARC significantly compromised plasma sulbactam concentration. HD sulbactam may be preferable for treating critically ill pediatric patients and those with ARC, especially during the empirical period.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pharmacokinetic and pharmacodynamic analysis of cefoperazone/sulbactam for the treatment of pediatric sepsis by Monte Carlo simulation

Abstract: Pediatric sepsis syndrome is one of the most common reasons for pediatric intensive care unit hospitalization (PICU). Cefoperazone/sulbactam is a time‐dependent beta-lactamase inhibitor combination which has been widely used in...

Cited by 2 publications

References 23 publications

Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

Simulation-based approaches for drug delivery systems: Navigating advancements, opportunities, and challenges

Therapeutic Drug Monitoring of High-dose Sulbactam in Pediatric Patients: Preliminary Data From a Prospective Observational Pharmacokinetic Study

Contact Info

Product

Resources

About